US FDA outlines broad vision for advancing regulatory science
This article was originally published in RAJ Devices
A new report outlining the US Food and Drug Administration's "broad vision" for advancing regulatory science focuses on seven public health areas that pose the most pressing challenges facing citizens1,2.
You may also be interested in...
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.